Type Public company Industry Pharmaceuticals Website www.genvec.com Founded 1992 | Traded as NASDAQ: GNVC Products CGF166 Number of employees 13 | |
 | ||
Key people Douglas J. Swirsky, President and CEO Stock price GNVC (NASDAQ) US$ 6.99 +0.20 (+2.95%)10 Mar, 4:00 PM GMT-5 - Disclaimer Headquarters Gaithersburg, Maryland, United States Profiles | ||
What is pump and dump scheme genvec inc gnvc
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
Contents
Genvec
References
GenVec Wikipedia(Text) CC BY-SA